PAH drug LTP001 safety study ends early – limited data available
NCT ID NCT05764265
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of the drug LTP001 in people with pulmonary arterial hypertension (PAH), a serious lung condition. It was an open-label extension for patients who had completed a previous study. However, the study was terminated early, and no one reached the full 52 weeks of treatment. Only 31 people took part, and final safety checks were done at the end of treatment instead.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LTP001 (a drug taken orally once daily)
What this could lead to
If successful, this could show that LTP001 is safe and effective for long-term use in managing pulmonary arterial hypertension.
What could go wrong
The study was terminated early with only 31 participants, so results are limited. No patients completed the full 52 weeks, making it hard to draw firm conclusions about long-term safety or benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Caba, Buenos Aires, C1025ABI, Argentina
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Amsterdam, North Holland, 1081 HV, Netherlands
-
Novartis Investigative Site
Krakow, 31 202, Poland
-
Novartis Investigative Site
Lodz, 91-347, Poland
-
Novartis Investigative Site
Wroclaw, 50-556, Poland
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28041, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Sheffield, South Yorkshire, S10 2JF, United Kingdom
-
Pulmonary Associates PA
Mesa, Arizona, 85206, United States